-
Product Insights
American Assets Trust – AAT Square Mixed-Use Development – Oregon
Equip yourself with the essential tools needed to make informed and profitable decisions with our American Assets Trust - AAT Square Mixed-Use Development - Oregon report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Electroencephelographs (EEG) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
EEG Pipeline Market Report Overview Electroencephalograms are used to diagnose issues related to the electrical activity of the brain. The EEG consists of electrodes placed on the scalp that records brain wave patterns. EEGs are used to detect various brain-related conditions, including seizures, head injuries, brain tumors, sleep disorders, stroke, and dementia. One unit refers to one EEG machine. The EEG pipeline market research report provides comprehensive information about the EEG pipeline products with a comparative analysis of the products...
-
Company Profile
Inhibrx Inc – Company Profile
Inhibrx Inc (Inhibrx) is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-101, a recombinant human AAT-Fc fusion protein candidate for the treatment of AATD (alpha-1 antitrypsin deficiency); INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating the INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1...
Add to Basket -
Company Profile
Kamada Pharmaceuticals – Company Profile
Kamada Pharmaceuticals (Kamada), is a biopharmaceutical company that develops, manufactures, and commercializes specialty proteins, specific immunoglobulins, and other prescription medicines. Its major products include respiratory, immunoglobins, critical care, and others. It also offers medicines for the treatment of cystic fibrosis, asthma, hemophilia, rabies, hepatitis B and other indications. Kamada's pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for Graft vs Host Disease (GVHD), type-1 diabetes, covid-19, and lung transplantation indications. The company distributes...
Add to Basket -
Company Profile
Arrowhead Pharmaceuticals Inc – Company Profile
Arrowhead Pharmaceuticals Inc (Arrowhead), formerly Arrowhead Research Corp, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AAT-008
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AAT-008 Drug Details AAT-008 (RQ-8) is under development for the treatment of arthrosis deformation...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AAT-009
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AAT-009 Drug Details AAT-009 is under development for the treatment of dementia. AAT-009 acts...
-
Product Insights
Net Present Value Model: ALNAAT-02
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ALNAAT-02 Drug Details ALNAAT-02 is under...
-
Product Insights
Net Present Value Model: Fazirsiran sodium
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Fazirsiran sodium Drug Details ARO-AAT is...
-
Product Insights
Net Present Value Model: INBRX-101
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model INBRX-101 Drug Details INBRX-101 is under...